We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Momenta Pharmaceuticals Inc | NASDAQ:MNTA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 52.48 | 47.70 | 52.45 | 0 | 01:00:00 |
1. Name and Address of Reporting Person * BELTRAMELLO JO ANN | 2. Issuer Name and Ticker or Trading Symbol MOMENTA PHARMACEUTICALS INC [ MNTA ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief HR and Inf. Officer |
3. Date of Earliest Transaction
(MM/DD/YYYY)
| ||
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
1.Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code (Instr. 8) |
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
CommonStock | 1/14/2020 | M(1) | 2362 | A | $10.83 | 46078 | D | |||
Common Stock | 1/14/2020 | M(3) | 30800 | A | $12.58 | 76878 | D | |||
Common Stock | 1/14/2020 | M(3) | 36485 | A | $13.02 | 113363 | D | |||
Common Stock | 1/14/2020 | M(3) | 25495 | A | $13.26 | 138858 | D | |||
Common Stock | 1/14/2020 | M(3) | 26183 | A | $15.44 | 165041 | D | |||
Common Stock | 1/14/2020 | S(1) | 2362 | D | $21.35 (2) | 162679 | D | |||
Common Stock | 1/14/2020 | S(3) | 30800 | D | $22.58 | 131879 | D | |||
Common Stock | 1/14/2020 | S(3) | 36485 | D | $23.02 | 95394 | D | |||
Common Stock | 1/14/2020 | S(3) | 25495 | D | $23.26 | 69899 | D | |||
Common Stock | 1/14/2020 | S(3) | 26183 | D | $25.44 | 43716 | D | |||
Common Stock | 1/14/2020 | S(1) | 1264 | D | $20.47 | 42452 | D |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Stock Option (Right to Buy) | $10.83 | 1/14/2020 | M (1) | 1493 | 2/9/2019 | 2/9/2026 | Common Stock | 1493 | $0 | 6843 | D | ||||
Stock Option (Right to Buy) | $10.83 | 1/14/2020 | M (1) | 869 | 2/9/2017 | 2/9/2026 | Common Stock | 869 | $0 | 28595 | D | ||||
Stock Option (Right to Buy) | $13.26 | 1/14/2020 | M (3) | 11240 | 2/22/2015 | 2/22/2021 | Common Stock | 11240 | $0 | 0 | D | ||||
Stock Option (Right to Buy) | $13.26 | 1/14/2020 | M (3) | 14255 | 11/22/2013 | 2/22/2021 | Common Stock | 14255 | $0 | 0 | D | ||||
Stock Option (Right to Buy) | $12.58 | 1/14/2020 | M (3) | 22935 | 11/19/2016 | 2/19/2023 | Common Stock | 22935 | $0 | 0 | D | ||||
Stock Option (Right to Buy) | $12.58 | 1/14/2020 | M (3) | 7895 | 2/19/2017 | 2/19/2023 | Common Stock | 7895 | $0 | 0 | D | ||||
Stock Option (Right to Buy) | $13.02 | 1/14/2020 | M (3) | 36485 | 11/18/2018 | 2/18/2025 | Common Stock | 36485 | $0 | 0 | D | ||||
Stock Option (Right to Buy) | $15.44 | 1/14/2020 | M (3) | 19357 | 11/14/2015 | 2/14/2022 | Common Stock | 19357 | $0 | 0 | D | ||||
Stock Option (Right to Buy) | $15.44 | 1/14/2020 | M (3) | 6826 | 2/14/2016 | 2/14/2022 | Common Stock | 6826 | $0 | 0 | D |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
BELTRAMELLO JO ANN C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY ST, CAMBRIDGE, MA 02142 | Chief HR and Inf. Officer |
Signatures | ||
/s/ R. Mark Chamberlin as attorney in fact | 1/16/2020 | |
**Signature of Reporting Person | Date |
1 Year Momenta Pharmaceuticals Chart |
1 Month Momenta Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions